Institute of Pathology, Christian-Albrechts-University, Arnold-Heller-Str. 3, D-24105 Kiel, Germany.
Expert Rev Mol Diagn. 2011 Nov;11(8):799-802. doi: 10.1586/erm.11.75.
Evaluation of: Magnin S, Viel E, Baraquin A et al. A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers. J. Mol. Diagn. 13(5), 485-492 (2011). Since mutations in the KRAS and BRAF genes are associated with resistance to therapy with anticancer drugs targeting the EGF receptor pathway, the analysis of KRAS and BRAF mutational status has become an important tool in the clinical management of patients with advanced colorectal cancer. To be useful in the clinical setting, a diagnostic assay has to address several issues related to the sensitivity and specificity of the method, the modularity of the assay, the turnaround time and the running costs. A variety of methods have been applied to the diagnosis of KRAS and BRAF mutational status. Although there is a good concordance between different methods, differences exist regarding sensitivity, multiplexing capacity and costs. In this article, we review a recently published assay for the simultaneous detection of diagnostically relevant KRAS and BRAF mutations and discuss this work in the context of conventional diagnostic methods.
Magnin S, Viel E, Baraquin A 等人。一种用于快速检测晚期结直肠癌中 KRAS 和 BRAF 突变的多重 SNaPshot 检测法。J. Mol. Diagn. 13(5), 485-492 (2011)。由于 KRAS 和 BRAF 基因的突变与针对表皮生长因子受体途径的抗癌药物治疗的耐药性有关,因此分析 KRAS 和 BRAF 突变状态已成为晚期结直肠癌患者临床管理的重要工具。为了在临床环境中有用,诊断检测法必须解决与方法的灵敏度和特异性、检测法的模块化、周转时间和运行成本相关的几个问题。已经应用了多种方法来诊断 KRAS 和 BRAF 突变状态。尽管不同方法之间存在很好的一致性,但在灵敏度、多重检测能力和成本方面存在差异。在本文中,我们回顾了最近发表的一种用于同时检测诊断相关 KRAS 和 BRAF 突变的检测法,并在传统诊断方法的背景下讨论了这项工作。